Zhelev N - Search Results

1

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).

McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP. McClue SJ, et al. Among authors: zhelev n. Int J Cancer. 2002 Dec 10;102(5):463-8. doi: 10.1002/ijc.10738. Int J Cancer. 2002. PMID: 12432547 Free article.

2

Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.

Zheleva DI, McInnes C, Gavine AL, Zhelev NZ, Fischer PM, Lane DP. Zheleva DI, et al. Among authors: zhelev nz. J Pept Res. 2002 Nov;60(5):257-70. doi: 10.1034/j.1399-3011.2002.21014.x. J Pept Res. 2002. PMID: 12383116

3

A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics.

Zheleva DI, Zhelev NZ, Fischer PM, Duff SV, Warbrick E, Blake DG, Lane DP. Zheleva DI, et al. Among authors: zhelev nz. Biochemistry. 2000 Jun 27;39(25):7388-97. doi: 10.1021/bi992498r. Biochemistry. 2000. PMID: 10858286

4

Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin.

Wang S, Zhelev NZ, Duff S, Fischer PM. Wang S, et al. Bioorg Med Chem Lett. 2006 May 15;16(10):2628-31. doi: 10.1016/j.bmcl.2006.02.035. Epub 2006 Mar 2. Bioorg Med Chem Lett. 2006. PMID: 16513344

5

Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin.

Fischer PM, Zhelev NZ, Wang S, Melville JE, Fåhraeus R, Lane DP. Fischer PM, et al. Among authors: zhelev nz. J Pept Res. 2000 Feb;55(2):163-72. doi: 10.1034/j.1399-3011.2000.00163.x. J Pept Res. 2000. PMID: 10784032

6

New lupane derived compounds with pro-apoptotic activity in cancer cells: synthesis and structure-activity relationships.

Sarek J, Klinot J, Dzubák P, Klinotová E, Nosková V, Krecek V, Korínková G, Thomson JO, Janost'áková A, Wang S, Parsons S, Fischer PM, Zhelev NZ, Hajdúch M. Sarek J, et al. J Med Chem. 2003 Dec 4;46(25):5402-15. doi: 10.1021/jm020854p. J Med Chem. 2003. PMID: 14640549

7

Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.

Kovárová H, Hajdúch M, Korínková G, Halada P, Krupicková S, Gouldsworthy A, Zhelev N, Strnad M. Kovárová H, et al. Among authors: zhelev n. Electrophoresis. 2000 Nov;21(17):3757-64. doi: 10.1002/1522-2683(200011)21:17<3757::AID-ELPS3757>3.0.CO;2-X. Electrophoresis. 2000. PMID: 11271495

8

Bioluminescent imaging of Cdk2 inhibition in vivo.

Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberg DS, Shapiro G, Kaelin WG Jr. Zhang GJ, et al. Among authors: zhelev n. Nat Med. 2004 Jun;10(6):643-8. doi: 10.1038/nm1047. Epub 2004 May 2. Nat Med. 2004. PMID: 15122251

9

New deletion in LAMP2 causing familial Danon disease. Effect of the X-chromosome inactivation.

Sivitskaya L, Vaikhanskaya T, Danilenko N, Liaudanski A, Davydenko O, Zhelev N. Sivitskaya L, et al. Among authors: zhelev n. Folia Med (Plovdiv). 2022 Oct 31;64(5):853-862. doi: 10.3897/folmed.64.e66292. Folia Med (Plovdiv). 2022. PMID: 36876541

10

Supercooling of the A phase of ³He.

Tian Y, Lotnyk D, Eyal A, Zhang K, Zhelev N, Abhilash TS, Chavez A, Smith EN, Hindmarsh M, Saunders J, Mueller E, Parpia JM. Tian Y, et al. Among authors: zhelev n. Nat Commun. 2023 Jan 10;14(1):148. doi: 10.1038/s41467-022-35532-7. Nat Commun. 2023. PMID: 36627275 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

53 results

Search Page